Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy

Hao, Zhaonian; Li, Ruyuan; Wang, Yuanyuan; Li, Shuangying; Hong, Zhenya; Han, Zhiqiang

doi:10.1186/s40364-021-00333-5

Cited by 49 publications

(36 citation statements)

References 252 publications

(224 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S26A). Increased myelopoiesis and MDSC expansion have been observed in various types of cancers, such as NSCLC and head and neck cancers (HNCs) ( 38 ). Consistent with previous reports, we found that both PMN-MDSCs and M-MDSCs were increased in the blood of NSCLC patients (fig.…”

Section: Serum α-Msh Concentration Is Elevated and Correlates With Ci...mentioning

confidence: 99%

Pituitary hormone α-MSH promotes tumor-induced myelopoiesis and immunosuppression

Yan

Tao

et al. 2022

Science

View full text Add to dashboard Cite

The hypothalamic-pituitary (HP) unit can produce various hormones to regulate immune responses and some of its downstream hormones or effectors are elevated in cancer patients. We show that HP unit can promote myelopoiesis and immunosuppression to accelerate tumor growth. Subcutaneous implantation of tumors induced hypothalamus activation and pituitary α-melanocyte stimulating hormone (α-MSH) production in mice. α-MSH acted on bone marrow progenitors to promote myelopoiesis, myeloid cell accumulation, immunosuppression and tumor growth through its receptor MC5R. MC5R peptide antagonist boosted antitumor immunity and anti-programmed cell death protein 1 (anti-PD-1) immunotherapy. Serum α-MSH concentration was elevated and correlated with circulating myeloid-derived suppressor cells (MDSCs) in cancer patients. Our results reveal a neuroendocrine pathway which suppresses tumor immunity, and suggest MC5R as a potential target for cancer immunotherapy.

show abstract

Section: Serum α-Msh Concentration Is Elevated and Correlates With Ci...mentioning

confidence: 99%

Pituitary hormone α-MSH promotes tumor-induced myelopoiesis and immunosuppression

Yan

Tao

et al. 2022

Science

View full text Add to dashboard Cite

show abstract

“…The chronic inflammatory state generated via the accumulation of cytokines and growth factors promotes the recruitment and induction of immunosuppressive cells, such as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) [ 20 ]. MDSCs are a heterogeneous group of immature granulocytic and monocytic cells that are induced and activated by TME-derived factors and confer immunosuppressive activities [ 24 ]. Of note, granulocytic MDSCs and polymorphonuclear granulocytes (PMNs) display a strongly overlapping immunophenotype and can be distinguished only by gradual differences in marker expression [ 25 ] and their functional activity.…”

Section: Tumor-induced Immune Modulationmentioning

confidence: 99%

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?

Kuske

Haist

Jung

et al. 2022

Cancers

View full text Add to dashboard Cite

The approval of immune checkpoint inhibitors (ICI) that serve to enhance effector T-cell anti-tumor responses has strongly improved success rates in the treatment of metastatic melanoma and other tumor types. The currently approved ICI constitute monoclonal antibodies blocking cytotoxic T-lymphocyte-associated protein (CTLA)-4 and anti-programmed cell death (PD)-1. By this, the T-cell-inhibitory CTLA-4/CD80/86 and PD-1/PD-1L/2L signaling axes are inhibited. This leads to sustained effector T-cell activity and circumvents the immune evasion of tumor cells, which frequently upregulate PD-L1 expression and modulate immune checkpoint molecule expression on leukocytes. As a result, profound clinical responses are observed in 40–60% of metastatic melanoma patients. Despite the pivotal role of T effector cells for triggering anti-tumor immunity, mounting evidence indicates that ICI efficacy may also be attributable to other cell types than T effector cells. In particular, emerging research has shown that ICI also impacts innate immune cells, such as myeloid cells, natural killer cells and innate lymphoid cells, which may amplify tumoricidal functions beyond triggering T effector cells, and thus improves clinical efficacy. Effects of ICI on non-T cells may additionally explain, in part, the character and extent of adverse effects associated with treatment. Deeper knowledge of these effects is required to further develop ICI treatment in terms of responsiveness of patients to treatment, to overcome resistance to ICI and to alleviate adverse effects. In this review we give an overview into the currently known immunomodulatory effects of ICI treatment in immune cell types other than the T cell compartment.

show abstract

“…Additionally, bladder cancer cells or BCG treatment recruit and activate type 2 innate lymphoid cell (ILC2) to produce IL-13 that can amplify MDSC recruitment and induction via CXCL2/MIF-CXCR2 signaling [ 82 , 83 ]. Recruited MDSCs have been associated with progression and tumor-induced immune dysfunction [ 75 , 84 , 85 , 86 , 87 ]. Mechanistically, the enrichment with suppressive molecules such as Arg1, iNOS, ROS, PDL-1, and P-STAT3 enabled MDSCs in BC tissues to effectively suppress T-cell proliferation [ 83 ].…”

Section: Tumor Microenvironment In Bladder Cancermentioning

confidence: 99%

The Urinary Microbiome: Role in Bladder Cancer and Treatment

Friedrich

Choi

2022

Diagnostics

View full text Add to dashboard Cite

Commensal microbes have increasingly been found to be involved in the development and progression of cancer. The recent discovery of the urinary microbiome bolstered the notion that microbes might play a role in bladder cancer. Although microbial involvement in bladder neoplastic transformation and metastatic progression, except schisto somiasis, has not been established, accumulating research suggests that dysbiosis of the urinary microbiome can produce a chronically inflammatory urothelial microenvironment and lead to bladder cancer. In this review, we describe how the urinary microbiome might facilitate the development of bladder cancer by altering the host immune system and the kind of cytokines that are directly involved in these responses. We investigated the therapeutic possibilities of modulating the urinary microbiome, including immune checkpoint therapy. The responsiveness of patients to intravesical Bacillus Calmette-Guerin therapy was evaluated with respect to microbiome composition. We conclude by noting that the application of microbes to orchestrate the inflammatory response in the bladder may facilitate the development of treatments for bladder cancer.

show abstract

Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy

Cited by 49 publications

References 252 publications

Pituitary hormone α-MSH promotes tumor-induced myelopoiesis and immunosuppression

Pituitary hormone α-MSH promotes tumor-induced myelopoiesis and immunosuppression

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?

The Urinary Microbiome: Role in Bladder Cancer and Treatment

Contact Info

Product

Resources

About